SCHEMBL1690283

SCHEMBL1690283

CC1(C)OB(c2cnc(OCC(F)(F)C(F)F)c(C(F)(F)F)c2)OC1(C)C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 3/20 0.51
DGAT1 O75907 2/20 0.35
MAPK1 P28482 1/20 0.33
ALPL P05186 1/20 0.32
PDGFRB P09619 1/20 0.32
KDR P35968 1/20 0.32
FFAR1 O14842 1/20 0.32
GSK3A P49840 1/20 0.31
GSK3B P49841 1/20 0.31
CFTR P13569 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
CYP2D6 P10635 1/20 0.30
MAPT P10636 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL365904 0.86 AAK1 (0.51) AAK1DGAT1MAPK1ALPLPDGFRB
SCHEMBL2389323 0.84 AAK1 (0.47) AAK1DGAT1ALPLPDGFRBKDR
SCHEMBL16046359 0.81 AAK1 (0.44) AAK1DGAT1ALPLPDGFRBKDR
SCHEMBL2409875 0.80 AAK1 (0.47) AAK1DGAT1ALPLPDGFRBKDR
SCHEMBL20203987 0.76 AAK1 (0.50) AAK1DGAT1ALPLPDGFRBKDR
SCHEMBL20191051 0.76 AAK1 (0.53) AAK1DGAT1ALPLPDGFRBKDR
SCHEMBL17248007 0.75 SSTR4 (0.46) AAK1MAPK1CFTRKDM4EMEN1
SCHEMBL25870156 0.75 AAK1 (0.52) AAK1DGAT1ALPLPDGFRBKDR
SCHEMBL15555039 0.75 AAK1 (0.49) AAK1DGAT1ALPLPDGFRBKDR
SCHEMBL17609622 0.74 AAK1 (0.39) AAK1DGAT1ALPLPDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593432-B1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2014-10-22 EP disclosed
EP-2593432-B1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2014-10-22 EP disclosed
US-8592629-B2 Sulfonamide derivatives as Nav 1.7 inhibitors PFIZER LIMITED (GB) 2013-11-26 US disclosed
WO-2012007861-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010183-A1 Chemical Compounds SCN1A, SCN1B, SCN7A AAK1 1882/4885DGAT1 891/4885MAPK1 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.